Printer Friendly

The European Commission grants marketing authorisation to Actelion's Ledaga.

M2 PHARMA-March 9, 2017-The European Commission grants marketing authorisation to Actelion's Ledaga

(C)2017 M2 COMMUNICATIONS

The European Commission has granted marketing authorisation to Switzerland-based Actelion for its Ledaga (chlormethine gel) 160 micrograms/g intended to treat mycosis fungoides-type cutaneous T-cell lymphoma, it was reported yesterday.

The product is formulated as a topical, once-daily and colourless gel.

The approval was based on the results of the pivotal 201 study, which included around 260 patients. In the randomised controlled study, around 77% of patients within the efficacy evaluable population who have been treated for around six months with chlormethine gel indicated a clinical response in the composite assessment of index lesion severity score, while 59% of those treated with the compounded control had a clinical response. The 201 is a multicenter, observer-blinded, active-controlled and 12-month trial that included Stage I and IIA MF-type CTCL patients.

Since 2013, the chlormethine gel has been marketed in the US under the brand name Valchlor (mechlorethamine).

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 9, 2017
Words:172
Previous Article:BeiGene (Hong Kong) to set up joint venture with Guangzhou GET Technology Development.
Next Article:Novo Nordisk considering acquisition of Global Blood Therapeutics.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters